<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18453">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02086110</url>
  </required_header>
  <id_info>
    <org_study_id>450072</org_study_id>
    <nct_id>NCT02086110</nct_id>
  </id_info>
  <brief_title>Effect of Milk Oligosaccharides and Bifidobacteria on the Intestinal Microflora of Children With Autism</brief_title>
  <official_title>A Pilot Study Examining Microbiota Composition in Children With Autism and Gastrointestinal Symptoms After Use of Bifidobacterium Infantis and Milk Oligosaccharides</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the tolerability of dietary supplements and if
      these supplements can promote a healthy bacterial environment in the intestines of children
      with autism spectrum disorders and gastrointestinal complaints.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study investigates the feasibility, tolerability, and effects of a dietary supplement
      on the intestinal flora of children with autism spectrum disorders. This study is divided
      into two parts, each five weeks long, with a two week break in between. During one part of
      the study, a prebiotic (milk oligosaccharides from bovine colostrum) will be given. During
      the other part of the study, the synbiotic composed of the prebiotic and probiotic
      (bifidobacterium infantis) will be given.  Stool will be analyzed at the end of each study
      arm to determine content of bifidobacteria.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Stool Microbiota Composition</measure>
    <time_frame>Five weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The stool microbiome composition will be analyzed through next generation sequencing and quantitative polymerase chain reaction. Both the overall bacterial composition will be analyzed as well as specific Bifidobacteria species present.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Immune Profile</measure>
    <time_frame>5 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Luminex technology will be used to determine a serum immune profile of each participants in response to the study supplement. This profile will include pro-inflammatory cytokines (IFNg, IL-1, IL-6, IL-13 and TNFa) and anti-inflammatory cytokines (IL-10 and TGFb1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Immunoglobin Level</measure>
    <time_frame>Five weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>An ELISA (enzyme-linked immunosorbent assay) will be used to determine participants' immunoglobulin (Ig) levels (IgA, IgG and IgM) in response to the study supplement.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Autism</condition>
  <arm_group>
    <arm_group_label>Prebiotic first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will receive bovine milk oligosaccharides, administered orally twice per day for a daily total of 0.3 g per pound of body weight.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Synbiotic first</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will receive Bifidobacterium infantis (10 billion CFU) twice a day plus 0.3 g per pound body weight of bovine milk oligosaccharides in two divided doses per day orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Synbiotic</intervention_name>
    <arm_group_label>Prebiotic first</arm_group_label>
    <arm_group_label>Synbiotic first</arm_group_label>
    <other_name>Bifidobacterium infantis SC268</other_name>
    <other_name>bovine colostrum, bovine oligosaccharides</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Prebiotic</intervention_name>
    <arm_group_label>Prebiotic first</arm_group_label>
    <arm_group_label>Synbiotic first</arm_group_label>
    <other_name>bovine colostrum, bovine oligosaccharides</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Autism

          -  Diarrhea and/or constipation

        Exclusion Criteria:

          -  Milk protein or other documented food allergy

          -  Lactose intolerance

          -  Compromised Immunity

          -  GI conditions (inflammatory bowel disease, celiac disease, short gut, etc.)

          -  Systemic steroid, antifungal, or antibiotic use within a month of starting the study

          -  Failure to thrive

          -  Medically prescribed diets or supplements (including probiotic use within the past
             month).

          -  Vegetarian or dairy restricted diet

          -  Other medical conditions (seizures, genetic disorders, liver/pancreatic disease,
             cystic fibrosis, etc.)

          -  Medications that interfere or alter intestinal motility or microbiota composition.

          -  Full scale intelligence quotient (IQ) &lt;40
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen Angkustsiri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UC Davis MIND Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jonathan Polussa, BS</last_name>
    <phone>916.703.0477</phone>
    <email>jonathan.polussa@ucdmc.ucdavis.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC Davis MIND Institute</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 11, 2014</lastchanged_date>
  <firstreceived_date>March 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Davis</investigator_affiliation>
    <investigator_full_name>Kathleen Angkustsiri, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>probiotic</keyword>
  <keyword>prebiotic</keyword>
  <keyword>autism</keyword>
  <keyword>oligosaccharides</keyword>
  <keyword>Bifidobacterium infantis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Autistic Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
